JP7575272B2 - ヒトニューレグリン-1(nrg-1)組換え型融合タンパク質組成物及びその使用方法 - Google Patents

ヒトニューレグリン-1(nrg-1)組換え型融合タンパク質組成物及びその使用方法 Download PDF

Info

Publication number
JP7575272B2
JP7575272B2 JP2020556258A JP2020556258A JP7575272B2 JP 7575272 B2 JP7575272 B2 JP 7575272B2 JP 2020556258 A JP2020556258 A JP 2020556258A JP 2020556258 A JP2020556258 A JP 2020556258A JP 7575272 B2 JP7575272 B2 JP 7575272B2
Authority
JP
Japan
Prior art keywords
fusion protein
recombinant fusion
recombinant
pharmaceutical composition
nrg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020556258A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021535727A5 (cg-RX-API-DMAC7.html
JP2021535727A (ja
Inventor
リャン ホア
ポンイー ルオ
ヤン ワン
リー ジョン
ションウェイ リー
ティーシアン ルオ
イーラン ウー
ミン チョウ
チョアン シアオレイ
Original Assignee
サルブリス バイオセラピューティクス,インコーポレイティド
サルブリス (チョントゥー) バイオテック,カンパニー,リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66484143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7575272(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by サルブリス バイオセラピューティクス,インコーポレイティド, サルブリス (チョントゥー) バイオテック,カンパニー,リミティド filed Critical サルブリス バイオセラピューティクス,インコーポレイティド
Publication of JP2021535727A publication Critical patent/JP2021535727A/ja
Publication of JP2021535727A5 publication Critical patent/JP2021535727A5/ja
Priority to JP2023097663A priority Critical patent/JP7631420B2/ja
Application granted granted Critical
Publication of JP7575272B2 publication Critical patent/JP7575272B2/ja
Priority to JP2025017265A priority patent/JP2025072502A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
JP2020556258A 2018-04-11 2019-04-11 ヒトニューレグリン-1(nrg-1)組換え型融合タンパク質組成物及びその使用方法 Active JP7575272B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023097663A JP7631420B2 (ja) 2018-04-11 2023-06-14 ヒトニューレグリン-1(nrg-1)組換え型融合タンパク質組成物及びその使用方法
JP2025017265A JP2025072502A (ja) 2018-04-11 2025-02-05 ヒトニューレグリン-1(nrg-1)組換え型融合タンパク質組成物及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862656246P 2018-04-11 2018-04-11
US62/656,246 2018-04-11
PCT/US2019/026889 WO2019200033A1 (en) 2018-04-11 2019-04-11 Human neuregulin-1 (nrg-1) recombinant fusion protein compositions and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023097663A Division JP7631420B2 (ja) 2018-04-11 2023-06-14 ヒトニューレグリン-1(nrg-1)組換え型融合タンパク質組成物及びその使用方法

Publications (3)

Publication Number Publication Date
JP2021535727A JP2021535727A (ja) 2021-12-23
JP2021535727A5 JP2021535727A5 (cg-RX-API-DMAC7.html) 2022-04-19
JP7575272B2 true JP7575272B2 (ja) 2024-10-29

Family

ID=66484143

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020556258A Active JP7575272B2 (ja) 2018-04-11 2019-04-11 ヒトニューレグリン-1(nrg-1)組換え型融合タンパク質組成物及びその使用方法
JP2023097663A Active JP7631420B2 (ja) 2018-04-11 2023-06-14 ヒトニューレグリン-1(nrg-1)組換え型融合タンパク質組成物及びその使用方法
JP2025017265A Pending JP2025072502A (ja) 2018-04-11 2025-02-05 ヒトニューレグリン-1(nrg-1)組換え型融合タンパク質組成物及びその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023097663A Active JP7631420B2 (ja) 2018-04-11 2023-06-14 ヒトニューレグリン-1(nrg-1)組換え型融合タンパク質組成物及びその使用方法
JP2025017265A Pending JP2025072502A (ja) 2018-04-11 2025-02-05 ヒトニューレグリン-1(nrg-1)組換え型融合タンパク質組成物及びその使用方法

Country Status (26)

Country Link
US (3) US11046741B2 (cg-RX-API-DMAC7.html)
EP (2) EP4361177A3 (cg-RX-API-DMAC7.html)
JP (3) JP7575272B2 (cg-RX-API-DMAC7.html)
KR (2) KR20260061438A (cg-RX-API-DMAC7.html)
CN (2) CN118909141A (cg-RX-API-DMAC7.html)
AU (2) AU2019252262B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020020646A2 (cg-RX-API-DMAC7.html)
CA (1) CA3096420A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020002621A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020012621A2 (cg-RX-API-DMAC7.html)
DK (1) DK3774859T3 (cg-RX-API-DMAC7.html)
EA (1) EA202092458A1 (cg-RX-API-DMAC7.html)
ES (1) ES2980163T3 (cg-RX-API-DMAC7.html)
FI (1) FI3774859T3 (cg-RX-API-DMAC7.html)
HU (1) HUE066892T2 (cg-RX-API-DMAC7.html)
IL (2) IL322374A (cg-RX-API-DMAC7.html)
MX (2) MX2020010740A (cg-RX-API-DMAC7.html)
MY (1) MY204230A (cg-RX-API-DMAC7.html)
PE (1) PE20210111A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020551648A1 (cg-RX-API-DMAC7.html)
PL (1) PL3774859T3 (cg-RX-API-DMAC7.html)
PT (1) PT3774859T (cg-RX-API-DMAC7.html)
SG (1) SG11202009831UA (cg-RX-API-DMAC7.html)
TW (2) TWI888027B (cg-RX-API-DMAC7.html)
WO (1) WO2019200033A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202006536B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3774859T3 (da) 2018-04-11 2024-05-27 Salubris Biotherapeutics Inc Sammensætninger af rekombinante fusionsproteiner af human neuregulin-1 (nrg-1) og fremgangsmåder til anvendelse deraf
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
US12649769B2 (en) 2019-09-16 2026-06-09 Zensun (Shanghai) Science & Technology, Co., Ltd. Recombinant human neuregulin derivatives and use thereof
CN114420310B (zh) * 2022-01-18 2024-11-12 河南大学 基于图转换网络的药物ATC Code预测方法
AU2023233680A1 (en) * 2022-03-15 2024-10-17 Salubris Biotherapeutics, Inc. Methods of treating fibrosis and arrhythmia with a neuregulin-1 fusion protein
CN116832040B (zh) * 2023-06-12 2026-01-13 北京市心肺血管疾病研究所 细胞周期蛋白依赖性激酶抑制剂在治疗射血分数保留型心力衰竭中的应用
WO2025122581A1 (en) * 2023-12-08 2025-06-12 The Trustees Of Indiana University Compositions comprising neuregulin and methods of using the same to treat or prevent neurotrophic keratitis
TW202612723A (zh) 2024-05-21 2026-04-01 美商信立泰生物醫藥公司 神經調節蛋白-1 her3融合蛋白及其治療用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009515819A (ja) 2005-10-07 2009-04-16 アーメイゲン・テクノロジーズ・インコーポレイテッド 血液脳関門輸送用融合タンパク質
JP2009517055A (ja) 2005-12-02 2009-04-30 ゼンサン (シャンハイ) サイエンス アンド テクノロジー リミテッド ニューレグリン変異体、並びにそれをスクリーニングし、及び使用する方法
US20130196911A1 (en) 2010-03-24 2013-08-01 Massachusetts Institute Of Technology Methods and compositions for cardioprotection and cardioregeneration
JP2017503784A (ja) 2014-04-10 2017-02-02 第一三共株式会社 抗her3抗体−薬物コンジュゲート

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5530109A (en) 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US5716930A (en) 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
IL101943A0 (en) * 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US5834229A (en) 1991-05-24 1998-11-10 Genentech, Inc. Nucleic acids vectors and host cells encoding and expressing heregulin 2-α
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
US5912326A (en) 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
AUPP785098A0 (en) * 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
AU2002304965A1 (en) * 2002-05-24 2003-12-12 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
AU2005271902B2 (en) 2004-07-09 2011-12-08 Wayne State University Hybrid proteins with erbB4 extracellular domain and neuregulin heparin-binding domain for targeting
RU2010119556A (ru) 2007-10-16 2011-11-27 Симфоген А/С (Dk) Композиции, содержащие оптимизированные мультимеры her1 и her3, и способы их применения
US20090226435A1 (en) * 2008-03-08 2009-09-10 Sanjay Khare Engineered fusion molecules immunotherapy in cancer and inflammatory diseases
KR20110040886A (ko) * 2008-07-08 2011-04-20 아보트 러보러터리즈 프로스타글란딘 e2 결합 단백질 및 이의 용도
JP5743898B2 (ja) 2008-11-28 2015-07-01 ゼンサン (シャンハイ) サイエンス アンド テクノロジー リミテッド ニューレグリンペプチド及びその使用
CA2775573A1 (en) * 2009-10-09 2011-04-14 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-her 3 antibodies
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun (Shanghai)Science & Technology Limited Compositions and methods for treating heart failure
WO2015067986A1 (en) * 2013-11-07 2015-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Neuregulin allosteric anti-her3 antibody
CN110946993A (zh) 2014-01-03 2020-04-03 上海泽生科技开发股份有限公司 纽兰格林制剂的配方
US10526416B2 (en) * 2014-09-08 2020-01-07 Yeda Research And Development Co. Ltd. Anti-HER3 antibodies and uses of same
CN111407882A (zh) 2014-10-17 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
JP7014724B2 (ja) 2016-02-06 2022-02-01 エピムアブ バイオセラピューティクス インコーポレイテッド タンデム型Fab免疫グロブリンおよびその使用
KR102469700B1 (ko) 2016-09-15 2022-11-23 우니베르지테트 스튜트가르트 Her3에 대한 항원 결합 단백질
DK3774859T3 (da) 2018-04-11 2024-05-27 Salubris Biotherapeutics Inc Sammensætninger af rekombinante fusionsproteiner af human neuregulin-1 (nrg-1) og fremgangsmåder til anvendelse deraf

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009515819A (ja) 2005-10-07 2009-04-16 アーメイゲン・テクノロジーズ・インコーポレイテッド 血液脳関門輸送用融合タンパク質
JP2009517055A (ja) 2005-12-02 2009-04-30 ゼンサン (シャンハイ) サイエンス アンド テクノロジー リミテッド ニューレグリン変異体、並びにそれをスクリーニングし、及び使用する方法
US20130196911A1 (en) 2010-03-24 2013-08-01 Massachusetts Institute Of Technology Methods and compositions for cardioprotection and cardioregeneration
JP2017503784A (ja) 2014-04-10 2017-02-02 第一三共株式会社 抗her3抗体−薬物コンジュゲート

Also Published As

Publication number Publication date
ES2980163T3 (es) 2024-09-30
MX2025002112A (es) 2025-05-02
NZ768694A (en) 2024-10-25
MX2020010740A (es) 2021-01-20
IL277790B2 (en) 2026-01-01
KR20210022542A (ko) 2021-03-03
IL277790B1 (en) 2025-09-01
PE20210111A1 (es) 2021-01-19
AU2019252262B2 (en) 2023-10-05
TWI834654B (zh) 2024-03-11
AU2023285793B2 (en) 2026-01-22
TW202426470A (zh) 2024-07-01
PL3774859T3 (pl) 2024-10-14
EP4361177A2 (en) 2024-05-01
JP2025072502A (ja) 2025-05-09
CN118909141A (zh) 2024-11-08
US11046741B2 (en) 2021-06-29
DK3774859T3 (da) 2024-05-27
US20230322877A1 (en) 2023-10-12
WO2019200033A1 (en) 2019-10-17
ZA202006536B (en) 2026-04-29
US20210347841A1 (en) 2021-11-11
IL322374A (en) 2025-09-01
EP4361177A3 (en) 2024-08-14
PH12020551648A1 (en) 2021-07-26
CL2020002621A1 (es) 2021-06-11
CA3096420A1 (en) 2019-10-17
CN113166218B (zh) 2024-08-13
KR102949228B1 (ko) 2026-04-06
PT3774859T (pt) 2024-05-27
US20200010522A1 (en) 2020-01-09
JP2023134436A (ja) 2023-09-27
EP3774859B1 (en) 2024-03-13
TW201945389A (zh) 2019-12-01
EA202092458A1 (ru) 2021-02-08
TWI888027B (zh) 2025-06-21
FI3774859T3 (fi) 2024-05-24
AU2019252262A1 (en) 2020-10-22
JP7631420B2 (ja) 2025-02-18
CN113166218A (zh) 2021-07-23
KR20260061438A (ko) 2026-05-06
BR112020020646A2 (pt) 2021-02-23
HUE066892T2 (hu) 2024-09-28
IL277790A (en) 2020-11-30
JP2021535727A (ja) 2021-12-23
CO2020012621A2 (es) 2020-12-21
AU2023285793A1 (en) 2024-01-18
US11718652B2 (en) 2023-08-08
MY204230A (en) 2024-08-16
EP3774859A1 (en) 2021-02-17
SG11202009831UA (en) 2020-11-27

Similar Documents

Publication Publication Date Title
JP7631420B2 (ja) ヒトニューレグリン-1(nrg-1)組換え型融合タンパク質組成物及びその使用方法
US20230045048A1 (en) Il-15 compositions and methods of use thereof
US20150299307A1 (en) Anti-vegf antibodies and their uses
US20250228917A1 (en) Methods of treating fibrosis and arrhythmia with a neuregulin-1 fusion protein
HK40106026A (en) Human neuregulin-1 (nrg-1) recombinant fusion protein compositions and methods of use thereof
EA046026B1 (ru) Композиции на основе рекомбинантного слитого белка, содержащего нейрегулин-1 (nrg-1) человека, и способы их применения
EA052095B1 (ru) Композиции на основе рекомбинантного слитого белка, содержащего нейрегулин-1 (nrg-1) человека, и способы их применения
HK40115251A (en) Method for treating fibrosis and arrhythmia with neuregulin-1 fusion protein
HK40044003B (en) Human neuregulin-1 (nrg-1) recombinant fusion protein compositions and methods of use thereof
HK40044003A (en) Human neuregulin-1 (nrg-1) recombinant fusion protein compositions and methods of use thereof
CN118922437A (zh) 用神经调节蛋白-1融合蛋白治疗纤维化及心律失常的方法
WO2025245112A1 (en) Neuregulin-1/anti-her3 antibody fusion protein for use in the treatment of heart failure

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220411

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220411

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231115

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240409

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240820

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241001

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241017

R150 Certificate of patent or registration of utility model

Ref document number: 7575272

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150